- Record: found
- Abstract: not found
- Article: not found
Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Empagliflozin, a sodium-glucose cotransporter 2 inhibitor, reduced cardiovascular
morbidity and mortality in patients with type 2 diabetes mellitus and established
cardiovascular disease in the EMPA-REG OUTCOME trial (Empagliflozin Cardiovascular
Outcome Event Trial in Type 2 Diabetes Mellitus Patients). Urinary glucose excretion
with empagliflozin decreases with declining renal function, resulting in less potency
for glucose lowering in patients with kidney disease. We investigated the effects
of empagliflozin on clinical outcomes in patients with type 2 diabetes mellitus, established
cardiovascular disease, and chronic kidney disease.